Literature DB >> 35210622

Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses.

Jeffrey A Tomalka1,2, Mehul S Suthar2,3, Steven G Deeks4, Rafick Pierre Sekaly5,6.   

Abstract

Host genetic and environmental factors including age, biological sex, diet, geographical location, microbiome composition and metabolites converge to influence innate and adaptive immune responses to vaccines. Failure to understand and account for these factors when investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine efficacy may impair the development of the next generation of vaccines. Most studies aimed at identifying mechanisms of vaccine-mediated immune protection have focused on adaptive immune responses. It is well established, however, that mobilization of the innate immune response is essential to the development of effective cellular and humoral immunity. A comprehensive understanding of the innate immune response and environmental factors that contribute to the development of broad and durable cellular and humoral immune responses to SARS-CoV-2 and other vaccines requires a holistic and unbiased approach. Along with optimization of the immunogen and vectors, the development of adjuvants based on our evolving understanding of how the innate immune system shapes vaccine responses will be essential. Defining the innate immune mechanisms underlying the establishment of long-lived plasma cells and memory T cells could lead to a universal vaccine for coronaviruses, a key biomedical priority.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35210622     DOI: 10.1038/s41590-022-01130-4

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  117 in total

1.  Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

Authors:  Nicole Doria-Rose; Mehul S Suthar; Mat Makowski; Sarah O'Connell; Adrian B McDermott; Britta Flach; Julie E Ledgerwood; John R Mascola; Barney S Graham; Bob C Lin; Sijy O'Dell; Stephen D Schmidt; Alicia T Widge; Venkata-Viswanadh Edara; Evan J Anderson; Lilin Lai; Katharine Floyd; Nadine G Rouphael; Veronika Zarnitsyna; Paul C Roberts; Mamodikoe Makhene; Wendy Buchanan; Catherine J Luke; John H Beigel; Lisa A Jackson; Kathleen M Neuzil; Hamilton Bennett; Brett Leav; Jim Albert; Pratap Kunwar
Journal:  N Engl J Med       Date:  2021-04-06       Impact factor: 91.245

2.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.

Authors:  Shengli Xia; Yuntao Zhang; Yanxia Wang; Hui Wang; Yunkai Yang; George Fu Gao; Wenjie Tan; Guizhen Wu; Miao Xu; Zhiyong Lou; Weijin Huang; Wenbo Xu; Baoying Huang; Huijuan Wang; Wei Wang; Wei Zhang; Na Li; Zhiqiang Xie; Ling Ding; Wangyang You; Yuxiu Zhao; Xuqin Yang; Yang Liu; Qian Wang; Lili Huang; Yongli Yang; Guangxue Xu; Bojian Luo; Wenling Wang; Peipei Liu; Wanshen Guo; Xiaoming Yang
Journal:  Lancet Infect Dis       Date:  2020-10-15       Impact factor: 25.071

3.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

4.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Authors:  Merryn Voysey; Sue Ann Costa Clemens; Shabir A Madhi; Lily Y Weckx; Pedro M Folegatti; Parvinder K Aley; Brian Angus; Vicky L Baillie; Shaun L Barnabas; Qasim E Bhorat; Sagida Bibi; Carmen Briner; Paola Cicconi; Andrea M Collins; Rachel Colin-Jones; Clare L Cutland; Thomas C Darton; Keertan Dheda; Christopher J A Duncan; Katherine R W Emary; Katie J Ewer; Lee Fairlie; Saul N Faust; Shuo Feng; Daniela M Ferreira; Adam Finn; Anna L Goodman; Catherine M Green; Christopher A Green; Paul T Heath; Catherine Hill; Helen Hill; Ian Hirsch; Susanne H C Hodgson; Alane Izu; Susan Jackson; Daniel Jenkin; Carina C D Joe; Simon Kerridge; Anthonet Koen; Gaurav Kwatra; Rajeka Lazarus; Alison M Lawrie; Alice Lelliott; Vincenzo Libri; Patrick J Lillie; Raburn Mallory; Ana V A Mendes; Eveline P Milan; Angela M Minassian; Alastair McGregor; Hazel Morrison; Yama F Mujadidi; Anusha Nana; Peter J O'Reilly; Sherman D Padayachee; Ana Pittella; Emma Plested; Katrina M Pollock; Maheshi N Ramasamy; Sarah Rhead; Alexandre V Schwarzbold; Nisha Singh; Andrew Smith; Rinn Song; Matthew D Snape; Eduardo Sprinz; Rebecca K Sutherland; Richard Tarrant; Emma C Thomson; M Estée Török; Mark Toshner; David P J Turner; Johan Vekemans; Tonya L Villafana; Marion E E Watson; Christopher J Williams; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard
Journal:  Lancet       Date:  2020-12-08       Impact factor: 79.321

5.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

6.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

Authors:  Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Hein Fennema; Bart Spiessens; Kim Offergeld; Gert Scheper; Kimberly L Taylor; Merlin L Robb; John Treanor; Dan H Barouch; Jeffrey Stoddard; Martin F Ryser; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Nancy Cauwenberghs; Tamzin Tanner; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih
Journal:  N Engl J Med       Date:  2021-04-21       Impact factor: 176.079

7.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.

Authors:  Paul T Heath; Eva P Galiza; David N Baxter; Marta Boffito; Duncan Browne; Fiona Burns; David R Chadwick; Rebecca Clark; Catherine Cosgrove; James Galloway; Anna L Goodman; Amardeep Heer; Andrew Higham; Shalini Iyengar; Arham Jamal; Christopher Jeanes; Philip A Kalra; Christina Kyriakidou; Daniel F McAuley; Agnieszka Meyrick; Angela M Minassian; Jane Minton; Patrick Moore; Imrozia Munsoor; Helen Nicholls; Orod Osanlou; Jonathan Packham; Carol H Pretswell; Alberto San Francisco Ramos; Dinesh Saralaya; Ray P Sheridan; Richard Smith; Roy L Soiza; Pauline A Swift; Emma C Thomson; Jeremy Turner; Marianne E Viljoen; Gary Albert; Iksung Cho; Filip Dubovsky; Greg Glenn; Joy Rivers; Andreana Robertson; Kathy Smith; Seth Toback
Journal:  N Engl J Med       Date:  2021-06-30       Impact factor: 91.245

8.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Authors:  Yanjun Zhang; Gang Zeng; Hongxing Pan; Changgui Li; Yaling Hu; Kai Chu; Weixiao Han; Zhen Chen; Rong Tang; Weidong Yin; Xin Chen; Yuansheng Hu; Xiaoyong Liu; Congbing Jiang; Jingxin Li; Minnan Yang; Yan Song; Xiangxi Wang; Qiang Gao; Fengcai Zhu
Journal:  Lancet Infect Dis       Date:  2020-11-17       Impact factor: 25.071

9.  Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.

Authors:  Dan H Barouch; Kathryn E Stephenson; Jerald Sadoff; Jingyou Yu; Aiquan Chang; Makda Gebre; Katherine McMahan; Jinyan Liu; Abishek Chandrashekar; Shivani Patel; Mathieu Le Gars; Anne M de Groot; Dirk Heerwegh; Frank Struyf; Macaya Douoguih; Johan van Hoof; Hanneke Schuitemaker
Journal:  N Engl J Med       Date:  2021-07-14       Impact factor: 91.245

View more
  6 in total

Review 1.  Immune response in COVID-19: what is next?

Authors:  Qing Li; Ying Wang; Qiang Sun; Jasmin Knopf; Martin Herrmann; Liangyu Lin; Jingting Jiang; Changshun Shao; Peishan Li; Xiaozhou He; Fei Hua; Zubiao Niu; Chaobing Ma; Yichao Zhu; Giuseppe Ippolito; Mauro Piacentini; Jerome Estaquier; Sonia Melino; Felix Daniel Weiss; Emanuele Andreano; Eicke Latz; Joachim L Schultze; Rino Rappuoli; Alberto Mantovani; Tak Wah Mak; Gerry Melino; Yufang Shi
Journal:  Cell Death Differ       Date:  2022-05-17       Impact factor: 12.067

2.  COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication.

Authors:  Tiago Azenha Rama; Joana Miranda; Diana Silva; Luís Amaral; Eunice Castro; Alice Coimbra; André Moreira; José Luís Plácido
Journal:  Vaccines (Basel)       Date:  2022-05-04

Review 3.  Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections.

Authors:  Murad Alahdal; Eyad Elkord
Journal:  Clin Transl Med       Date:  2022-08

4.  A Novel 3-Gene Signature for Identifying COVID-19 Patients Based on Bioinformatics and Machine Learning.

Authors:  Guichuan Lai; Hui Liu; Jielian Deng; Kangjie Li; Biao Xie
Journal:  Genes (Basel)       Date:  2022-09-08       Impact factor: 4.141

5.  Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital.

Authors:  Cristina Costa; Gitana Scozzari; Enrica Migliore; Claudia Galassi; Giovannino Ciccone; Guido Ricciardelli; Antonio Scarmozzino; Lorenzo Angelone; Paola Cassoni; Rossana Cavallo
Journal:  Vaccines (Basel)       Date:  2022-06-27

Review 6.  SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders.

Authors:  Jing Ouyang; Silvere D Zaongo; Vijay Harypursat; Xiaofang Li; Jean-Pierre Routy; Yaokai Chen
Journal:  Front Public Health       Date:  2022-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.